41 results about "Prognosis Marker" patented technology

The invention relates to application of tsRNA-3025a as a prognostic marker of acute myocardial infarction and a treatment target spot of myocardial ischemia reperfusion injury. A DNA (Deoxyribonucleic Acid) sequence corresponding to the tsRNA-3025a is shown as SEQ ID NO: 1: 5 '-ATCCTGCCGACTACGCCA-3'. The tsRNA-3025a can be used for treating acute myocardial infarction and myocardial ischemia reperfusion injury. In the aspect of prognosis, a detection kit is provided, and the risk of heart failure and short-term adverse events of a patient is evaluated by quantitatively detecting the expression level of the tsRNA. In the aspect of treatment, the invention provides the application of the anti-tagomir for inhibiting the function or expression of tsRNA-3025a in the preparation of the medicine for treating the myocardial ischemia reperfusion injury, and the anti-tagomir is subjected to specific chemical modification. A novel biomarker is provided for prognosis risk stratification of acute myocardial infarction, and an effective treatment strategy is provided for prevention and treatment of myocardial ischemia-reperfusion injury.

The invention discloses application of SHC3 as a diagnosis and prognosis marker and a treatment target of lung metastasis of breast cancer. The research shows that the expression of SHC3 in TNBC lung metastatic cells is remarkably up-regulated, and the up-regulation is closely related to the prognosis of TNBC patients; the increase of SHC3 expression is positively correlated with the migration ability of the TNBC cells, which proves that the SHC3 gene is obviously up-regulated in the TNBC cells of pneumophilic metastasis and can be used as a biomarker of lung metastasis of breast cancer; researches show that silence of SHC3 can significantly weaken the metastasis ability of TNBC and reduce the number of pulmonary metastasis nodules, overexpression of SHC3 can enhance the metastasis activity of TNBC, and SHC3 can be used as a therapeutic target of breast cancer pulmonary metastasis; the invention provides a new marker for prognosis of breast cancer and diagnosis of lung metastasis of breast cancer, and provides a new target and treatment strategy and direction for treatment of lung metastasis of breast cancer.

Disclosed is an isoform of hexokinase 1 (HK1), namely hexokinase 1b (HK1b), for use as a prognosis marker and as a specific target for use in treatment of cancer.

Disclosed in the present invention is a use of an MP1 gene copy number variation detection reagent in preparation of an NK / T cell lymphoma prognosis kit. The present invention further provides a detection kit comprising the LMP1 gene copy number variation detection reagent, a use thereof, and an NK / T cell lymphoma prognosis method. In the present invention, a copy number variation event of LMP1 gene in an EB virus genome is used as a novel prognosis marker, which has a good prediction value for the overall survival and progression-free survival prognosis of an NK / T cell lymphoma patient, and can realize more accurate and effective prognostic assessment for the NK / T cell lymphoma patient.

The invention discloses a prognosis marker and a dynamic prognosis prediction method for colorectal cancer liver metastasis. The method comprises the following steps: S1, acquiring clinical pathological characteristic data of a patient with colorectal cancer liver metastasis and a longitudinal laboratory marker measured during post-operation follow-up visit; s2, extracting a change trend of the longitudinal laboratory marker by utilizing multivariable function principal component analysis to obtain a principal component score; s3, training a random survival forest model by using the principal component score and the clinical pathological feature data to obtain a dynamic prediction model; s4, dynamically updating the score of the principal component based on a newly collected laboratory marker of postoperative follow-up visit of the patient, and outputting dynamic risk assessment results of the progression-free lifetime and the total lifetime of the patient through a dynamic prediction model; according to the method, the prediction model capable of dynamically evaluating the survival risk of the patient is constructed and updated by fusing the dynamic longitudinal laboratory marker and the static clinical pathological characteristics.

The invention relates to application of ADAMTS2 related to gastric cancer. The application comprises an application of the ADAMTS2 inhibitor in preparation of drugs for preventing, relieving and / or treating gastric cancer, an application of a reagent for detecting ADAMTS2 and / or COL3A1 in preparation of a kit or system for predicting gastric cancer prognosis, and a system or a prognosis instrument for predicting gastric cancer prognosis. The metalloproteinase ADAMTS2 is found to be remarkably and highly expressed in gastric cancer tissues and is associated with peritoneal metastasis and tumor dryness. Therefore, ADAMTS2 can be used as a diagnosis and prognosis marker and a treatment target of cervical cancer, and has a huge application prospect.

The application provides a molecular marker for evaluating the prognosis of cervical squamous cell carcinoma and adenocarcinoma and application thereof, and belongs to the technical field of biological detection. Through bioinformatics analysis methods such as multivariate statistical analysis, difference screening, single factor COX regression analysis and multi-factor COX regression analysis, the application obtains an adenine kinase 4 used for evaluating the prognosis marker of cervical squamous cell carcinoma and a brain sponge-shaped deformity 2 protein used for evaluating the prognosis biomarker of cervical adenocarcinoma. Based on the biomarkers of the application, a kit for evaluating cervical squamous cell carcinoma or adenocarcinoma is constructed, which is used for accurately evaluating the prognosis of cervical squamous cell carcinoma or adenocarcinoma.

The invention discloses application of MISP as a breast cancer diagnosis / prognosis marker and a treatment target. The in-depth study on the expression of MISP in breast cancer cells and the influence on malignant biological behaviors such as breast cancer proliferation shows that compared with normal breast epithelial cells, the MISP is highly expressed in the breast cancer cells, the expression of the MISP is highly related to poor clinical prognosis of breast cancer patients, and the proliferation of the breast cancer cells can be inhibited by reducing the expression of the MISP. A new biomarker is provided for diagnosis and prognosis of the breast cancer, a new target spot is provided for treatment of the breast cancer, and important scientific significance is achieved in the aspects of subsequent drug research and development, clinical treatment and the like.

The application discloses a liver cancer prognosis marker and application thereof, and the liver cancer prognosis marker comprises TXNRD1, HAO1, C1S, OPTN and SNX6. The application provides a group of liver cancer prognosis markers, and a liver cancer patient prognosis prediction model is constructed based on the liver cancer prognosis markers. The liver cancer prognosis markers are obtained through comprehensive gene expression levels, single cell analysis and spatial transcriptome analysis, and the diversity of the data set and the large sample quantity improve the reliability and universality of the liver cancer prognosis markers and the liver cancer patient prognosis prediction model.

A C1QBP protein can be used in preparation for an oral cancer screening or prognosis marker. A reagent for detecting a C1QBP protein expression level is in preparation for an oral cancer screening or prognosis kit. The C1QBP protein expression level in an oral mucosa tissue of a patient suffering from oral squamous cell carcinoma is found to be remarkably higher than that of a healthy patient. Using a reagent for detecting a C1QBP protein expression level for preparing a screening or prognosis kit of oral squamous cell carcinoma can realize effective screening or prognosis of oral squamous cell carcinoma.

The invention belongs to the technical field of biological medicine, and particularly relates to a biliary atresia differential diagnosis and prognosis marker and application thereof. The invention provides the application of the KRT17 expression level as a biliary atresia differential diagnosis and prognostic marker for the first time. KRT17 as a single marker has a relatively high diagnostic value (AUC = 0.880) for BA, the efficiency of KRT17 is superior to all conventional clinical liver function indexes, and when KRT17 is combined with alanine aminotransferase for use, the diagnostic accuracy can be further improved to AUC = 0.904, the KRT17 and CX3CL1 are optimally combined, and the AUC value is as high as 0.938. According to the technology, KRT17 is used as a novel biliary atresia differential diagnosis marker, the defects of an existing differential diagnosis system can be made up to a certain degree, the KRT17 is specifically and highly expressed in biliary atresia liver bile duct epithelial cells, normal control and disease control are not expressed, and therefore more accurate differential diagnosis can be provided clinically.

The invention is a divisional application of which the application number is 202411480045.3. The invention provides a pancreatic cancer diagnosis marker based on external vesicle miRNA (micro Ribonucleic Acid) and application of the pancreatic cancer diagnosis marker. The pancreatic cancer diagnosis or prognosis marker based on the extracellular vesicle miRNA relates to a miRNA combination with biological significance in serum or plasma extracellular vesicles, and does not take a conventional reference gene as a reference; the pancreatic cancer diagnosis model constructed by taking the expression quantity ratio of the paired miRNAs in the combination as the input characteristic of the model has high diagnosis sensitivity and specificity on pancreatic cancer, is suitable for different data centers, has good diagnosis stability, has great potential in early pancreatic cancer screening, and has good application prospects. The kit has important practical significance for early diagnosis or prognosis prediction of pancreatic cancer.

The application discloses application of TGM2 as a cervical cancer diagnosis, prognosis biomarker and therapeutic target. The application provides a new cervical cancer diagnosis and prognosis marker TGM2, which can clearly characterize the occurrence and development of cervical cancer; the marker presents specific high expression phenomenon in comparison with normal tissue in human clinical cervical cancer tissue; and the marker also presents high expression in human cervical cancer cell lines. Knocking down TGM2 can inhibit the proliferation and migration ability of cervical cancer cells; TGM2, as an enzyme, has high application potential as a diagnosis and treatment target. The application provides a new marker and target for the diagnosis, prognosis and treatment of cervical cancer, and can provide a new strategy and direction for the treatment of cervical cancer.

The invention specifically discloses an acute myelogenous leukemia prognostic marker and application thereof, and relates to the technical field of biological medicines. The invention provides an application of a protein lysine succinylation modification level as an acute myelogenous leukemia diagnosis and / or prognosis marker, and clinical data, cell experiments and animal experiments prove that the protein lysine succinylation modification level is related to AML prognosis and is a supplement of an existing prognosis system. Ksuc can be detected through a multi-parameter flow type technology, the method is simple, convenient and rapid, the experimental period is only several hours, Ksuc can be obtained when conventional immune typing detection is carried out at the beginning of diseases, and the experimental period is shorter than that of existing prognosis factors adopting next-generation sequencing, traditional PCR and the like. The invention provides a theoretical basis and an experimental basis for developing a new treatment strategy, and has good clinical transformation and clinical application prospects.

The application provides a lung adenocarcinoma prognosis marker and model, a lung adenocarcinoma prognosis model based on programmed cell death (PCD) related mRNA and lncRNA is constructed, and the biological function of the lncRNA model in lung adenocarcinoma is explored through bioinformatics analysis and experiments. The prognosis model covers all PCD pathways and various molecules, has a robust prognosis prediction accuracy, and can provide potential molecular targets for personalized treatment. The method of the application comprehensively constructs a lung adenocarcinoma diagnosis model suitable for Chinese population by using PCD related mRNA and lncRNA, enhances the recognition ability of tumor patient classification from multiple aspects, improves the accuracy and reliability of prognosis prediction, can provide strong support for promoting the personalized treatment strategy of lung adenocarcinoma patients, and is suitable for popularization and application.

The present invention belongs to the technical fields of disease diagnosis and treatment and molecular biology, and particularly relates to the application of HMGCL as a glioma diagnosis / prognosis marker and a therapeutic target. The present invention demonstrates for the first time that the expression of HMGCL increases with the increase in the malignancy degree of glioma and is negatively correlated with the survival rate. At the same time, the HMGCL lentivirus can significantly reduce the expression level of HMGCL in glioma, and the knockdown of HMGCL inhibits the proliferation and colony formation of glioma cells, and can be used as an effective target for the prevention and / or treatment of glioma. In addition, the present invention demonstrates that the specific knockdown of HMGCL can lead to a significant decrease in the level of histone acetylation modification in GBM cells. In summary, the HMGCL and its molecular mechanism provided by the present invention will contribute to the in-depth understanding of the pathogenesis of glioma, and will also contribute to providing potential biomarkers and therapeutic targets for the clinical diagnosis, prognosis evaluation, prevention and treatment of glioma, and therefore has good practical application value.

The application relates to the technical field of melanoma prognosis, and provides a construction method and a verification method of a melanoma prognosis model based on a lactation gene methylation feature. The DNA methylation data of a cancer genome atlas database is taken as a training set, and the DNA methylation data of a gene expression comprehensive database is taken as a verification set, so that the lactation-related gene methylation feature prognosis marker model of melanoma constructed has good external applicability. A methylation site pair matrix is constructed through the relative methylation order relationship of the methylation sites, so that the batch effect between different data sets is effectively avoided, and excellent robustness and clinical applicability are achieved. The methylation sites corresponding to the lactation-related gene set are taken as anchor points to perform hierarchical clustering and differential methylation site screening, functional sites related to prognosis are screened out, the reliability of the constructed prognosis marker model is improved, and the accuracy of prognosis prediction is improved.

The application belongs to the technical field of biological medicine, and particularly relates to an esophageal squamous carcinoma marker circRNA and application thereof, wherein the marker is hsa_circ_0001701, and the sequence of hsa_circ_0001701 is shown as SEQ ID NO. 1. The application further discloses application of the marker in preparation of an esophageal squamous carcinoma diagnosis and / or prognosis marker product. The application provides a new view for searching for a biomarker and a drug treatment target for clinical diagnosis and prognosis evaluation of esophageal squamous carcinoma, lays a foundation for related drug research, and has important significance for research and treatment of esophageal squamous carcinoma, and therefore has good practical application value.

The invention provides application of novel burkholderia cepacia as a marker for tumor diagnosis, screening, prediction or prognosis. The invention provides a qualitative and quantitative detection method for detecting the Burkholderia cenocepacia bacteria in the glioma for the first time. On one hand, through co-culture with Burkholderia cenocepacia bacteria, the malignant phenotypic capabilities of proliferation, invasion and the like of glioma cells can be remarkably enhanced; more importantly, the abundance value of the 16S rRNA gene of the Burkholderia cenocepacia bacteria can be used as a molecular marker for prognosis evaluation of the glioma and a target spot for treatment of the glioma. A new thought is provided for diagnosis of glioma, and important clinical value is achieved.

The invention discloses application of secretory LAMP1 as a non-small cell lung cancer immunotherapy curative effect and prognostic marker and an evaluation system, and relates to the technical field of biological medicine. According to the invention, sLAMP1 in serum is taken as a core biomarker, so that the curative effect and prognosis of ICB treatment of NSCLC patients can be effectively predicted. Meanwhile, a multi-dimensional prognosis evaluation system integrating sLAMP1 concentration, ECOG score, pathological subtype, gender, smoking state, age and other clinical pathological characteristics is constructed, and accurate prediction of one-year and three-year progression-free lifetime of the patient is realized. The system predicts that the AUC of PFS reaches up to 0.94 within 12 months, is easy to popularize in a standardized manner based on a mature ELISA platform, can assist clinicians in early screening of potential benefit crowds, identification of true and false progresses and timely adjustment of treatment strategies, can remarkably improve the precise whole-course management level of NSCLC immunotherapy, and has important clinical transformation value.

The invention provides an anti-human CD95 antibody and application thereof. The antibody comprises a heavy chain variable region and a light chain variable region, the CDR1, the CDR2 and the CDR3 of the heavy chain variable region are amino acid sequences as shown in SEQ ID NO. 1, SEQ ID NO. 2 and SEQ ID NO. 3 respectively; the CDR1, the CDR2 and the CDR3 of the light chain variable region are amino acid sequences as shown in SEQ ID NO. 4, SEQ ID NO. 5 and SEQ ID NO. 6 respectively. The anti-human CD95 antibody disclosed by the invention is detected by using a flow cytometry, and the expression condition of CD95 on cells is judged according to the intensity change of a CD95 fluorescence signal; the antibody has an important application value, can be used as a prognostic marker of some cancers, is used for detecting occurrence and related progression of the cancers, and can also be used for detecting apoptosis.

The present invention relates to the field of bioengineering technology, and discloses a hepatocellular carcinoma diagnosis and prognosis marker and its application, including a hepatocellular carcinoma diagnosis and prognosis marker biomarker, wherein the biomarker is TMEM64, and the expression of TMEM64 is correlated with NK cells, CD8 + The immune cell infiltration levels of T cells and pDCs were significantly negatively correlated, and the GSEA enrichment analysis found that the Wnt / β-catenin, JAK / STAT3, KRAS and P53 signaling pathways were significantly enriched in cells in the high TMEM64 expression group. The present invention found that TMEM64 expression was elevated in liver cancer tissues and cell lines, and its high expression level was associated with poor prognosis of patients; TMEM64 has good diagnostic value for liver cancer. TMEM64 can be used as a good diagnostic and prognostic marker for hepatocellular carcinoma; TMEM64 can promote the proliferation and invasion of liver cancer cells, may be involved in regulating the malignant progression of liver cancer, and is expected to become a molecular marker and potential therapeutic target for the diagnosis and prognosis of liver cancer.

The invention discloses a prognostic marker for bladder cancer and application of the prognostic marker. The prognostic marker for the bladder cancer comprises CD14T, CD68S, CD163T and S100A12S; wherein the CD14T and the CD163T respectively refer to CD14 and CD163 expressed in a bladder cancer tumor region, and the CD68S and the S100A12S respectively refer to CD68 and S100A12 expressed in a bladder cancer matrix region. The bladder cancer prognosis marker provided by the invention can be used for constructing a bladder cancer prognosis prediction model, and multi-queue verification proves that the model has a strong prediction capability on the postoperative survival condition of a BLC patient and is beneficial to postoperative risk assessment and clinical decision of the BLC patient.

The invention discloses application of AURKA and FTH1 as prognosis markers in preparation of a liver cancer prognosis prediction kit, and relates to the technical field of disease prognosis diagnosis. The invention provides application of AURKA and FTH1 as prognosis markers in preparation of a liver cancer prognosis prediction kit, and accurate evaluation of prognosis of a liver cancer patient is realized by evaluating the co-expression level (IRS double indexes are greater than or equal to 6) of AURKA and FTH1 proteins in tumor tissues.

The application discloses a method for screening a triple-negative breast cancer prognosis gene marker, uses gene expression data of triple-negative breast cancer, obtains genes interacting with a cell proliferation marker, and screens prognosis-related genes by means of single-factor Cox regression, and the application uses a Cox regression method with minimum maximum concave penalty to construct a prognosis risk assessment model, and obtains a prognosis gene marker and a prognosis assessment method capable of predicting and assessing the risk of triple-negative breast cancer. The application proposes a prognosis marker gene identification technology for triple-negative breast cancer which is a high-heterogeneity disease, and the technology can be applied and popularized in clinical treatment.

According to the coronary heart disease prognosis marker and the model thereof, risk stratification is carried out on coronary heart disease patients in a non-invasive, low-cost, safe, green and repeatable mode, early warning is carried out on the risk of cardiovascular adverse events of the coronary heart disease patients in the future, subsequent individualized precise treatment is achieved, survival prognosis of the patients is improved, and social disease burden is reduced. The method has very important clinical significance and social economic significance.

The application provides a gastric cancer prognosis marker and application thereof, and belongs to the technical field of biotechnology.The survival analysis is carried out to explore the prognosis correlation of m6A "writer" RBM15 in gastric cancer.The results prove that RBM15 is a prognosis marker related to better clinical results, and can be used to judge the prognosis of gastric cancer patients.The application verifies the relationship among RBM15, ECT2 and EMT signal pathway, and the results prove that RBM15 mediates the m6A methylation of ECT2 through IGF2BP3, influences the stability of ECT2 RNA, thereby influences the expression of ECT2, and simultaneously regulates the EMT signal pathway.The application also discloses the mechanism that RBM15 influences the proliferation, invasion, migration and sensitivity to 5-fluorouracil chemotherapy of gastric cancer cells, and provides a new treatment target for gastric cancer treatment.

The invention discloses application of glycosylated Y5RNA (Ribonucleic Acid) as a diagnosis and prognosis marker of pancreatic ductal adenocarcinoma. The key effect of the Glyco Y5RNA in PDAC immune escape and the clinical application value of the Glyco Y5RNA as a PDAC prognostic marker are disclosed for the first time, and experiments prove that the exosome Glyco Y5 generated under hypoxia induction can shape an immunosuppressive microenvironment by regulating immune cell functions, and new mechanism explanation is provided for malignant progression of PDAC.

The invention discloses an application of an NDUFA4L2 gene as a drug target for screening and treating neuroblastoma, and particularly relates to an application of the NDUFA4L2 gene as a drug target for screening and treating neuroblastoma, or as a prognostic marker of neuroblastoma, or as an indication marker of differentiation degree of neuroblastoma. The invention finds that NDUFA4L2 is remarkably high in expression in ganglion neuroma with the highest differentiation degree and is remarkably low in expression in neuroblastoma with the lowest differentiation degree. Prognostic analysis on NDUFA4L2 shows that high expression of NDUFA4L2 is related to better overall survival and event-free survival. According to the application, the differentiation promotion effect of NDUFA4L2 on neuroblastoma and the improvement effect of NDUFA4L2 on retinoic acid reactivity are respectively verified at in-vivo and in-vitro levels, tumor proliferation and metastasis of neuroblastoma can be indirectly inhibited, and a new biomarker for NB layered diagnosis and treatment and a new target for precise treatment are determined.

The invention discloses a hepatocellular carcinoma prognosis evaluation marker TKFC and application thereof, and belongs to the technical field of prognosis markers. By comparing tumor tissues of patients with different prognosis, the invention discovers that the HCC subtype with relatively strong invasiveness shows a systematic state imbalance, that is, the oxidative metabolism function represented by mitochondrial oxidative phosphorylation and tricarboxylic acid cycle is weakened, and the intracellular proliferation procedure related to chromatin remodeling and cell cycle progress is abnormally active. The state of low oxidative metabolism-high proliferation output may form the metabolism and epigenetic basis of malignant HCC. The low expression of the TKFC is obviously related to high-risk clinical pathological characteristics such as later tumor staging and higher occurrence rate of vascular invasion, and is an independent poor prognosis factor influencing the total lifetime of a patient, which indicates that the TKFC can be used as a prognosis biomarker of HCC.